

Author Index Volume 53 (2016)

The issue number is given in front of the pagination

- Aarsland, D. see Tajeddinn, W. (2) 621–630
Aarsland, D., see Brønnick, K. (4) 1277–1285
Aarsland, D., see Tajeddinn, W. (1) 349–361
Abdullah, M., H. Takase, M. Nunome, H. Enomoto, J.-i. Ito, J.-S. Gong and M. Michikawa, Amyloid- β Reduces Exosome Release from Astrocytes by Enhancing JNK Phosphorylation (4) 1433–1441
Abe, K., see Zhai, Y. (3) 893–905
Adams, H.H., see Chouraki, V. (3) 921–932
Adedokun, O.J., see Russu, A. (2) 535–546
Adiele, C.A., see Adiele, R.C. (4) 1257–1270
Adiele, R.C. and C.A. Adiele, Mitochondrial Regulatory Pathways in the Pathogenesis of Alzheimer's Disease (4) 1257–1270
Aerts, T., see Vermeiren, Y. (3) 1079–1096
Aguayo, L.G., see Peters, C. (1) 197–207
Ahmed, M.S., see Tajeddinn, W. (1) 349–361
Ahmed, M.S., see Tajeddinn, W. (2) 621–630
Ahmed, R., see Dermody, N. (3) 801–816
Akoudad, S., M.E. Gurol, P. Fotiadis, P.J. Koudstaal, A. Hofman, M.A. Ikram, S.M. Greenberg and M.W. Vernooij, Cerebral Microbleeds and Cerebrovascular Reactivity in the General Population: The EDAN Study (2) 497–503
Al Rihani, S.B., see Qosa, H. (4) 1499–1516
Albani, D., see Biella, G. (3) 1193–1207
Allen, H.B., Alzheimer's Disease: Assessing the Role of Spirochetes, Biofilms, the Immune System, and Amyloid- β with Regard to Potential Treatment and Prevention (4) 1271–1276
Allué, J.A., L. Sarasa, M. Izco, V. Pérez-Grijalba, N. Fandos, M. Pascual-Lucas, S. Ogueta, P. Pesini and M. Sarasa, Outstanding Phenotypic Differences in the Profile of Amyloid- β between Tg2576 and APPsw/PS1dE9 Transgenic Mouse Models of Alzheimer's Disease (3) 773–785
Almeida, M.R., see Luis, E. (1) 303–313
Amariglio, R.E., see Hsu, D.C. (3) 1097–1105
Amen, D.G., K. Willeumier, B. Omalu, A. Newberg, C. Raghavendra and C.A. Raji, Perfusion Neuroimaging Abnormalities Alone Distinguish National Football League Players from a Healthy Population (1) 237–241
Amouyel, P., see Chouraki, V. (3) 921–932
Andersson, C.-H., O. Hansson, L. Minthon, N. Andreasen, K. Blennow, H. Zetterberg, I. Skoog, A. Wallin, S. Nilsson and P. Kettunen, A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease (4) 1353–1363
Andreasen, N., see Andersson, C.-H. (4) 1353–1363
Andrew, M.K., see Armstrong, J.J. (3) 1003–1013
Annweiler, C., see Landel, V. (2) 419–444
Antequera-Torres, M., see Marín-Muñoz, J. (1) 73–78
Antúnez-Almagro, C., see Marín-Muñoz, J. (1) 73–78
Araújo, L.F., S.S. Mirza, D. Bos, W.J. Niessen, S.M. Barreto, A. van der Lugt, M.W. Vernooij, A. Hofman, H. Tiemeier and M.A. Ikram, Association of Coffee Consumption with MRI Markers and Cognitive Function: A Population-Based Study (2) 451–461
Arcuti, S., see Sassi, C. (2) 475–485
Arendash, G.W., Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer's Disease (3) 753–771
Arighi, A., see Galimberti, D. (2) 445–449
Armstrong, J.J., J. Godin, L.J. Launer, L.R. White, A. Mitnitski, K. Rockwood and M.K. Andrew, Changes in Frailty Predict Changes in Cognition in Older Men: The Honolulu-Asia Aging Study (3) 1003–1013
Arroyo, P., see Eugenin, J. (3) 857–873
Asahi, M., see Ueda, Y. (1) 315–325
Ash, E.L., see Yogev-Seligmann, G. (2) 517–533
Atanackovic, J., see Mohseni, H.K. (3) 933–942
Au, R., see Bangen, K.J. (4) 1553–1562
Aubert, I., see Maliszewska-Cyna, E. (1) 243–257
Ayers, E., see Callisaya, M.L. (3) 1043–1052
Back, J.H., see Roh, H.W. (2) 463–473
Bäckman, L., see Marseglia, A. (3) 1069–1078

- Baek, J.-H., see Kang, S. (4) 1563–1576
 Baez, S., see Pietto, M. (4) 1325–1340
 Bailey, K.R., see Kantarci, K. (2) 547–556
 Baldereschi, M., see Di Carlo, A. (2) 505–515
 Balducci, C., see Stravalaci, M. (4) 1485–1497
 Bálint, Á., see Kasza, Á. (2) 557–571
 Ballina, L., see Perkins, M. (1) 95–106
 Balogh, G., see Kasza, Á. (2) 557–571
 Bamji-Mirza, M., Y. Li, D. Najem, Q.Y. Liu, D. Walker, L.-F. Lue, J. Stupak, K. Chan, J. Li, M. Ghani, Z. Yang, E. Rogava and W. Zhang, Genetic Variations in *ABCA7* Can Increase Secreted Levels of Amyloid- β_{40} and Amyloid- β_{42} Peptides and *ABCA7* Transcription in Cell Culture Models (3) 875–892
 Bangen, K.J., J.J. Himali, A.S. Beiser, D.A. Nation, D.J. Libon, C.S. Fox, S. Seshadri, P.A. Wolf, A.C. McKee, R. Au and L. Delano-Wood, Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer's Disease Pathology (4) 1553–1562
 Barhum, Y., see Salomon-Zimri, S. (4) 1443–1458
 Barkhof, F., see Vijverberg, E.G.B. (4) 1287–1297
 Barreto, S.M., see Araújo, L.F. (2) 451–461
 Barros, H., see Moreira, A. (1) 85–93
 Barrows, R.J., see Paholpak, P. (1) 327–335
 Barulli, M.R., see Sassi, C. (2) 475–485
 Barzilai, N., see Callisaya, M.L. (3) 1043–1052
 Batarseh, Y.S., see Qosa, H. (4) 1499–1516
 Battle, A., see Merino-Zamorano, C. (2) 677–691
 Bayer, T.A., see Jakobsen, J.E. (4) 1617–1630
 Beckett, T.L., see Lovell, M.A. (1) 273–287
 Beeg, M., see Stravalaci, M. (4) 1485–1497
 Behbahani, H., see Tajeddinn, W. (2) 621–630
 Bei, B., see Cavuoto, M.G. (3) 943–953
 Beiser, A.S., see Bangen, K.J. (4) 1553–1562
 Beiser, A.S., see Camargo, E.C. (4) 1597–1608
 Belger, M., see Happich, M. (1) 171–183
 Bellenguez, C., see Chouraki, V. (3) 921–932
 Bennett, D.A., see Chouraki, V. (3) 921–932
 Ben-Sadoun, G., G. Sacco, V. Manera, J. Bourgeois, A. König, P. Foulon, B. Fosty, F. Bremond, F. d'Arripe-Longueville and P. Robert, Physical and Cognitive Stimulation Using an Exergame in Subjects with Normal Aging, Mild and Moderate Cognitive Impairment (4) 1299–1314
 Ben-Zur, T., see Salomon-Zimri, S. (4) 1443–1458
 Berg, D., see Glonnegger, H. (4) 1475–1484
 Bernáth, S., see Kasza, Á. (2) 557–571
 Bernocchi, O., see Biella, G. (3) 1193–1207
 Berr, C., see Chouraki, V. (3) 921–932
 Bertram, K., see Galimberti, D. (2) 445–449
 Bester, J., see Pretorius, E. (4) 1237–1256
 Beyle, A., see Glonnegger, H. (4) 1475–1484
 Biasini, E., see Stravalaci, M. (4) 1485–1497
 Bieberle, N.A., see Vidoni, E.D. (1) 161–170
 Biella, G., F. Fusco, E. Nardo, O. Bernocchi, A. Colombo, S.F. Lichtenthaler, G. Forloni and D. Albani, Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid- β Protein Precursor Processing in Two Alzheimer's Disease Mouse Models (3) 1193–1207
 Birnbaum, H.G., see Happich, M. (1) 171–183
 Bis, J.C., see Chouraki, V. (3) 921–932
 Bisconti, A.V., see Venturelli, M. (4) 1631–1640
 Black, J.R., see Vidoni, E.D. (1) 161–170
 Blennow, K., see Andersson, C.-H. (4) 1353–1363
 Blundell, K.L.I.M., see Kasza, Á. (2) 557–571
 Bobkova, N., V. Vorobyov, N. Medvinskaya, I. Nesterova, O. Tatarnikova, P. Nekrasov, A. Samokhin, A. Deev, F. Sengpiel, D. Koroev and O. Volpina, Immunization Against Specific Fragments of Neurotrophin p75 Receptor Protects Forebrain Cholinergic Neurons in the Olfactory Bulbectomized Mice (1) 289–301
 Boehm-Cagan, A., see Salomon-Zimri, S. (4) 1443–1458
 Bolívar, J.C.C. and D.G. Saladie, Redefining Amnesic Mild Cognitive Impairment as an Early Form of Alzheimer's Disease Based on Assessment of Memory Systems (2) 705–712
 Borroni, B., see Luis, E. (1) 303–313
 Bos, D., see Araújo, L.F. (2) 451–461
 Bots, M.L., see van de Vorst, I.E. (1) 117–125
 Bourgeois, J., see Ben-Sadoun, G. (4) 1299–1314
 Bouter, Y., see Jakobsen, J.E. (4) 1617–1630
 Boutoleau-Brettonnière, C., see Luis, E. (1) 303–313
 Bovis, F., see Di Carlo, A. (2) 505–515
 Bradley-Whitman, M., see Lovell, M.A. (1) 273–287
 Bramanti, P., see Naro, A. (4) 1375–1388
 Brashear, H.R., see Russo, A. (2) 535–546
 Brasioli, A., see Venturelli, M. (4) 1631–1640
 Breitive, M.H., see Brønnick, K. (4) 1277–1285
 Bremond, F., see Ben-Sadoun, G. (4) 1299–1314
 Brescia, V., see Sassi, C. (2) 475–485
 Brix, B., see Vanderstichele, H.M.J. (3) 1121–1132
 Brodtmann, A., H. Pemberton, D. Darby and A.P. Vogel, Diagnostic Distortions: A Case Report of Progressive Apraxia of Speech (1) 79–83
 Broeckhoven, C.V., see Luis, E. (1) 303–313
 Brønnick, K., M.H. Breitive, A. Rongve and D. Aarsland, Neurocognitive Deficits Distinguishing Mild Dementia with Lewy

- Bodies from Mild Alzheimer's Disease are Associated with Parkinsonism (4) 1277–1285
- Broster, L.S., see Yu, J. (2) 693–704
- Brothers, H.M., see Penninkilampi, R. (4) 1395–1404
- Bunai, T., see Oboshi, Y. (3) 817–830
- Burns, J.M., see Vidoni, E.D. (1) 161–170
- Buschke, H., see Mowrey, W.B. (4) 1585–1595
- Bustin, J., see Pietto, M. (4) 1325–1340
- Byun, S.H., see Mohseni, H.K. (3) 933–942
- Cai, D., see El Gaamouch, F. (1) 15–29
- Calabrò, R.S., see Naro, A. (4) 1375–1388
- Callesen, H., see Jakobsen, J.E. (4) 1617–1630
- Callisaya, M.L., E. Ayers, N. Barzilai, L. Ferrucci, J.M. Guralnik, R.B. Lipton, P. Othahal, V.K. Srikanth and J. Verghese, Motoric Cognitive Risk Syndrome and Falls Risk: A Multi-Center Study (3) 1043–1052
- Calvo-Garrido, J., see Tajeddinn, W. (1) 349–361
- Calvó-Perxas, L., see Garre-Olmo, J. (4) 1341–1351
- Camacho, A., see González, H.M. (3) 955–965
- Camargo, E.C., G. Weinstein, A.S. Beiser, Z.S. Tan, C. DeCarli, M. Kelly-Hayes, C. Kase, J.M. Murabito and S. Seshadri, Association of Physical Function with Clinical and Subclinical Brain Disease: The Framingham Offspring Study (4) 1597–1608
- Campanari, M.-L., F. Navarrete, S.D. Ginsberg, J. Manzanares, J. Sáez-Valero and M.-S. García-Ayllón, Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimer's Disease Patients (3) 831–841
- Cao, Y.-m. see Gao, H.-l. (3) 1173–1192
- Capozzo, R., see Sassi, C. (2) 475–485
- Caroppo, P., see Luis, E. (1) 303–313
- Carr, D.R., see Paholpak, P. (1) 327–335
- Cavuoto, M.G., B. Ong, K.E. Pike, C.L. Nicholas, B. Bei and G.J. Kinsella, Better Objective Sleep Quality in Older Adults with High Subjective Memory Decline (3) 943–953
- Cè, E., see Venturelli, M. (4) 1631–1640
- Cedazo-Minguez, A., see Tajeddinn, W. (1) 349–361
- Cedazo-Minguez, A., see Tajeddinn, W. (2) 621–630
- Cerff, B., see Glonnegger, H. (4) 1475–1484
- Cermakova, P., see Lovas, J. (2) 631–638
- Chan, K., see Bamji-Mirza, M. (3) 875–892
- Chang, C.-W., see Lin, C.-Y. (3) 1053–1067
- Chang, K.J., see Roh, H.W. (2) 463–473
- Chavira, B., see Perkins, M. (1) 95–106
- Chen, J., see Verma, N. (1) 259–272
- Chen, K., see Malek-Ahmadi, M. (4) 1641–1652
- Chen, K., see Zhang, J. (1) 185–195
- Chen, K.-Y., see Tang, W. (1) 221–236
- Chen, R.P.-Y., see Lin, C.-Y. (3) 1053–1067
- Chen, S., see Deng, Y. (4) 1419–1432
- Chen, Y., see Zhang, J. (1) 185–195
- Chen, Z.-t., see Lin, C.-Y. (3) 1053–1067
- Cheng, J., see Deng, Y. (4) 1419–1432
- Cheng, J., see Tang, W. (1) 221–236
- Cheng, X., see Wang, J. (3) 907–919
- Cheng, Y.-S., see Lin, C.-Y. (3) 1053–1067
- Chettle, D.R., see Mohseni, H.K. (3) 933–942
- Chiesa, R., see Stravalaci, M. (4) 1485–1497
- Cho, H.J., see Kang, S. (4) 1563–1576
- Choi, S.H., see Chouraki, V. (3) 921–932
- Choi, S.H., see Roh, H.W. (2) 463–473
- Chouraki, V., C. Reitz, F. Mauray, J.C. Bis, C. Bellenguez, L. Yu, J. Jakobsdottir, S. Mukherjee, H.H. Adams, S.H. Choi, E.B. Larson, A. Fitzpatrick, A.G. Uitterlinden, P.L. de Jager, A. Hofman, V. Gudnason, B. Vardarajan, C. Ibrahim-Verbaas, S.J. van der Lee, O. Lopez, J.-F. Dartigues, C. Berr, P. Amouyel, D.A. Bennett, C. van Duijn, A.L. DeStefano, L.J. Launer, M.A. Ikram, P.K. Crane, J.-C. Lambert, R. Mayeux and S. Seshadri for the International Genomics of Alzheimer's Project, Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease (3) 921–932
- Chow, M., see Verma, N. (1) 259–272
- Christianson, T.J., see Krell-Roesch, J. (4) 1609–1616
- Chung, Y.K., see Roh, H.W. (2) 463–473
- Cioffi, S.M.G., see Galimberti, D. (2) 445–449
- Coart, E., see Vanderstichele, H.M.J. (3) 1121–1132
- Colombo, A., see Biella, G. (3) 1193–1207
- Colom-Cadena, M., see Pickett, E.K. (3) 787–800
- Colosimo, C., see Galimberti, D. (2) 445–449
- Colpo, G.D., see Salem, H. (3) 1209–1230
- Conde-Sala, J.L., see Perales, J. (3) 1133–1143
- Cooper, S.K., see Vidoni, E.D. (1) 161–170
- Copetti, M., see Sassi, C. (2) 475–485
- Coppedè, F., see Grossi, E. (4) 1517–1522
- Corallo, F., see Naro, A. (4) 1375–1388
- Cornejo, F., see Eugenin, J. (3) 857–873
- Corrigan, B., see Russu, A. (2) 535–546
- Cowan, D., see Mohseni, H.K. (3) 933–942
- Crane, P.K., see Chouraki, V. (3) 921–932
- Crews, C., see Sassi, C. (2) 475–485
- Cronin, H., see Feeney, J. (3) 1107–1114
- Csoti, I., see Glonnegger, H. (4) 1475–1484
- Cunha, G., see Luis, E. (1) 303–313

- D'Agata, F., see Luis, E. (1) 303–313
- d'Arripe-Longueville, F., see Ben-Sadoun, G. (4) 1299–1314
- Darby, D., see Brodtmann, A. (1) 79–83
- Dartigues, J.-F., see Chouraki, V. (3) 921–932
- Dartigues, J.-F., see Dumurgier, J. (4) 1411–1418
- David, R., V. Manera, R. Fabre, C. Pradier, P. Robert and K. Tifratene, Evolution of the Antidepressant Prescribing in Alzheimer's Disease and Related Disorders Between 2010 and 2014: Results from the French National Database on Alzheimer's Disease (BNA) (4) 1365–1373
- Daviglus, M.L., see González, H.M. (3) 955–965
- De Deyn, P.P., see Vermeiren, Y. (3) 1079–1096
- de Jager, P.L., see Chouraki, V. (3) 921–932
- de Jonge, R., see Willemse, E.A.J. (1) 107–116
- De La Fuente, A., see Neugroschl, J. (1) 69–72
- De Luca, R., see Naro, A. (4) 1375–1388
- de Mendonça, A., see Moreira, A. (1) 85–93
- De Roeck, E., see De Vos, A. (4) 1523–1538
- De Salvo, S., see Naro, A. (4) 1375–1388
- De Vos, A., H. Struyfs, D. Jacobs, E. Fransen, T. Klewansky, E. De Roeck, C. Robberecht, C. Van Broeckhoven, C. Duyckaerts, S. Engelborghs and E. Vanmechelen, The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease (4) 1523–1538
- DeCarli, C., see Camargo, E.C. (4) 1597–1608
- Deev, A., see Bobkova, N. (1) 289–301
- del Valle, E., A. Navarro, E. Martínez-Pinilla, S. Torices and J. Tolivia, Apo J and Apo D: Complementary or Antagonistic Roles in Alzheimer's Disease? (2) 639–650
- Delano-Wood, L., see Bangen, K.J. (4) 1553–1562
- Demeyer, L., see Vanderstichele, H.M.J. (3) 1121–1132
- Deng, Y., J. Wei, J. Cheng, P. Zhong, Z. Xiong, A. Liu, L. Lin, S. Chen and Z. Yan, Partial Amelioration of Synaptic and Cognitive Deficits by Inhibiting Cofilin Dephosphorylation in an Animal Model of Alzheimer's Disease (4) 1419–1432
- Dermody, N., S. Wong, R. Ahmed, O. Piguët, J.R. Hodges and M. Irish, Uncovering the Neural Bases of Cognitive and Affective Empathy Deficits in Alzheimer's Disease and the Behavioral-Variant of Frontotemporal Dementia (3) 801–816
- Desai, U., see Happich, M. (1) 171–183
- Despa, F., see Verma, N. (1) 259–272
- DeStefano, A.L., see Chouraki, V. (3) 921–932
- Di Carlo, A., M. Baldereschi, M. Lamassa, F. Bovis, M. Inzitari, V. Solfrizzi, F. Panza, L. Galluzzo, E. Scafato and D. Inzitari for the Italian Longitudinal Study on Aging Working Group, Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study (2) 505–515
- Di Iorio, R., see Rossini, P.M. (4) 1389–1393
- Di Lorenzo, G., see Naro, A. (4) 1375–1388
- Di Meco, A. and D. Praticò, MicroRNAs as Therapeutic Targets for Alzheimer's Disease (2) 367–372
- Diógenes, M.J., see Moreira, A. (1) 85–93
- Diomede, L., see Stravalaci, M. (4) 1485–1497
- Dols, A., see Vijverberg, E.G.B. (4) 1287–1297
- Dong, Y., see Woody, S.K. (3) 1015–1031
- Donovan, N.J., see Hsu, D.C. (3) 1097–1105
- Dricot, L., see Hanseeuw, B. (2) 651–660
- Dumurgier, J., J.-F. Dartigues, A. Gabelle, C. Paquet, M. Prevot, J. Hugon and C. Tzourio, Time Orientation and 10 Years Risk of Dementia in Elderly Adults: The Three-City Study (4) 1411–1418
- Duong, Q.-V., see Qosa, H. (4) 1499–1516
- Durieux-Lu, S., see Willemse, E.A.J. (1) 107–116
- Duthie, M., see Jakobsen, J.E. (4) 1617–1630
- Duyckaerts, C., see De Vos, A. (4) 1523–1538
- Egeto, P., see Hird, M.A. (2) 713–729
- El Gaamouch, F., P. Jing, J. Xia and D. Cai, Alzheimer's Disease Risk Genes and Lipid Regulators (1) 15–29
- Emilsson, L.S., see Farnsworth, B. (1) 209–219
- Engelborghs, S., see De Vos, A. (4) 1523–1538
- Enomoto, H., see Abdullah, M. (4) 1433–1441
- Eriksdotter, M., see Garre-Olmo, J. (4) 1341–1351
- Eriksdotter, M., see Lovas, J. (2) 631–638
- Erkinjuntti, T., see Skrobot, O.A. (3) 981–989
- Eslick, G.D., see Penninkilampi, R. (4) 1395–1404
- Esposito, F., see Venturelli, M. (4) 1631–1640
- Eudave, L., see Luis, E. (1) 303–313
- Eugenin, J., A. Vecchiola, P. Murgas, P. Arroyo, F. Cornejo and R. von Bernhardi, Expression Pattern of Scavenger Receptors and Amyloid- β Phagocytosis of Astrocytes and Microglia in Culture are Modified by Acidosis: Implications for Alzheimer's Disease (3) 857–873
- Fabre, R., see David, R. (4) 1365–1373
- Fandos, N., see Allué, J.A. (3) 773–785

- Farnsworth, B., C. Peuckert, B. Zimmermann, E. Jazin, P. Kettunen and L.S. Emilsson, Gene Expression of Quaking in Sporadic Alzheimer's Disease Patients is Both Upregulated and Related to Expression Levels of Genes Involved in Amyloid Plaque and Neurofibrillary Tangle Formation (1) 209–219
- Feeney, J., G.M. Savva, C. O'Regan, B. King-Kallimanis, H. Cronin and R.A. Kenny, Measurement Error, Reliability, and Minimum Detectable Change in the Mini-Mental State Examination, Montreal Cognitive Assessment, and Color Trails Test among Community Living Middle-Aged and Older Adults (3) 1107–1114
- Feistel, B., see Hofrichter, J. (3) 967–980
- Feng, T., see Zhai, Y. (3) 893–905
- Fenoglio, C., see Galimberti, D. (2) 445–449
- Fereshtehnejad, S.-M., see Lovas, J. (2) 631–638
- Fereshtehnejad, S.-M., see Tajeddinn, W. (2) 621–630
- Fernández-de Retana, S., see Merino-Zamorano, C. (2) 677–691
- Fernández-Pérez, E.J., see Peters, C. (1) 197–207
- Féron, F., see Landel, V. (2) 419–444
- Ferrucci, L., see Callisaya, M.L. (3) 1043–1052
- Fields, J.A., see Kantarci, K. (2) 547–556
- Fischer, C.E., see Hird, M.A. (2) 713–729
- Fister, S., see Lovell, M.A. (1) 273–287
- Fitzpatrick, A., see Chouraki, V. (3) 921–932
- Flores, F., see Pietto, M. (4) 1325–1340
- Forloni, G., see Biella, G. (3) 1193–1207
- Forloni, G., see Stravalaci, M. (4) 1485–1497
- Formica, A., see Galimberti, D. (2) 445–449
- Fosty, B., see Ben-Sadoun, G. (4) 1299–1314
- Fotiadis, P., see Akoudad, S. (2) 497–503
- Foulon, P., see Ben-Sadoun, G. (4) 1299–1314
- Fox, C.S., see Bangen, K.J. (4) 1553–1562
- Francis, P., see Tajeddinn, W. (1) 349–361
- Frank, Z., see Kasza, Á. (2) 557–571
- Fransen, E., see De Vos, A. (4) 1523–1538
- Fraser, P.E., see Jakobsen, J.E. (4) 1617–1630
- Fratiglioni, L., see Marseglia, A. (3) 1069–1078
- Fukui, Y., see Zhai, Y. (3) 893–905
- Fülöp, F., see Kasza, Á. (2) 557–571
- Funke, S.A., see Schuster, J. (1) 53–67
- Fusco, F., see Biella, G. (3) 1193–1207
- Gabelle, A., see Dumurgier, J. (4) 1411–1418
- Gainotti, G., see Trojano, L. (1) 31–52
- Galimberti, D., K. Bertram, A. Formica, C. Fenoglio, S.M.G. Cioffi, A. Arighi, E. Scarpini and C. Colosimo, Plasma Screening for Progranulin Mutations in Patients with Progressive Supranuclear Palsy and Corticobasal Syndromes (2) 445–449
- Galimberti, D., see Luis, E. (1) 303–313
- Galluzzo, L., see Di Carlo, A. (2) 505–515
- Gao, H.-l., C. Li, H. Nabeka, T. Shimokawa, Z.-Y. Wang, Y.-m. Cao and S. Matsuda, An 18-mer Peptide Derived from Prosaposin Ameliorates the Effects of A β ₁₋₄₂ Neurotoxicity on Hippocampal Neurogenesis and Memory Deficit in Mice (3) 1173–1192
- García, A.M., see Pietto, M. (4) 1325–1340
- García-Ayllón, M.-S., see Campanari, M.-L. (3) 831–841
- Garcia-Ptacek, S., see Garre-Olmo, J. (4) 1341–1351
- Garre-Olmo, J., S. Garcia-Ptacek, L. Calvó-Perxas, O. Turró-Garriga, S. López-Pousa and M. Eriksdotter, Diagnosis of Dementia in the Specialist Setting: A Comparison Between the Swedish Dementia Registry (SveDem) and the Registry of Dementias of Girona (ReDeGi) (4) 1341–1351
- Gascón-Bayarri, J., see Perales, J. (3) 1133–1143
- Gazzina, S., see Luis, E. (1) 303–313
- Geda, Y.E., see Krell-Roesch, J. (4) 1609–1616
- Geng, Y., see Han, B. (4) 1539–1552
- Ghani, M., see Bamji-Mirza, M. (3) 875–892
- Gibbs, R., see Sassi, C. (2) 475–485
- Giladi, N., see Yogev-Seligmann, G. (2) 517–533
- Ginsberg, S.D., see Campanari, M.-L. (3) 831–841
- Glat, M.J., see Salomon-Zimri, S. (4) 1443–1458
- Gleason, C., see Kantarci, K. (2) 547–556
- Glönnegger, H., A. Beyle, B. Cerff, S. Gräber, I. Csoti, D. Berg and I. Liepelt-Scarfone, The Multiple Object Test as a Performance Based Tool to Assess Cognitive Driven Activity of Daily Living Function in Parkinson's Disease (4) 1475–1484
- Gobbi, M., see Stravalaci, M. (4) 1485–1497
- Godin, J., see Armstrong, J.J. (3) 1003–1013
- Gómez-Tortosa, E., see Marín-Muñoz, J. (1) 73–78
- Gong, J.-S., see Abdullah, M. (4) 1433–1441
- González, H.M., W. Tarraf, N. Goukova, C.J. Rodríguez, T. Rundek, E. Grober, A. Pirzada, P. González, P.L. Lutsey, A. Camacho, M.L. Daviglius, C. Wright and T.H. Mosley, Life's Simple 7's Cardiovascular Health Metrics are Associated with Hispanic/Latino Neurocognitive Function: HCHS/SOL Results (3) 955–965
- González, P., see González, H.M. (3) 955–965
- Gosselet, F., see Merino-Zamorano, C. (2) 677–691

- Gossink, F., see Vijverberg, E.G.B. (4) 1287–1297
 Goto, Y., see Yamasaki, T. (2) 661–676
 Gousskova, N., see González, H.M. (3) 955–965
 Gräber, S., see Glonnegger, H. (4) 1475–1484
 Granata, G., see Rossini, P.M. (4) 1389–1393
 Graves, R.S., see Vidoni, E.D. (1) 161–170
 Greenberg, S.M., see Akoudad, S. (2) 497–503
 Greer, C.S., see Vidoni, E.D. (1) 161–170
 Grober, E., see González, H.M. (3) 955–965
 Grossi, E., A. Stoccoro, P. Tannorella, L. Migliore and F. Coppedè, Artificial Neural Networks Link One-Carbon Metabolism to Gene-Promoter Methylation in Alzheimer's Disease (4) 1517–1522
 Grothe, M.J., see Peter, J. (3) 991–1001
 Gudnason, V., see Chouraki, V. (3) 921–932
 Guralnik, J.M., see Callisaya, M.L. (3) 1043–1052
 Gurol, M.E., see Akoudad, S. (2) 497–503
 Gustafson, D., see Wennberg, A.M.V. (2) 573–581
- Habekost, M., see Jakobsen, J.E. (4) 1617–1630
 Hagen, C.E., see Wennberg, A.M.V. (2) 573–581
 Han, B., L. Yu, Y. Geng, L. Shen, H. Wang, Y. Wang, J. Wang and M. Wang, Chronic Stress Aggravates Cognitive Impairment and Suppresses Insulin Associated Signaling Pathway in APP/PS1 Mice (4) 1539–1552
 Han, G., see Suh, S.W. (2) 731–741
 Han, J.W., see Suh, S.W. (2) 731–741
 Han, S.-H., see Kang, S. (4) 1563–1576
 Han, Z.-M., see Tang, W. (1) 221–236
 Hannequin, D., see Luis, E. (1) 303–313
 Hanseeuw, B., L. Dricot, R. Lhommel, L. Quenon and A. Ivanoiu, Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved (2) 651–660
 Hansson, O., see Andersson, C.-H. (4) 1353–1363
 Hansson, O., see Vanderstichele, H.M.J. (3) 1121–1132
 Happich, M., N.Y. Kirson, U. Desai, S. King, H.G. Birnbaum, C. Reed, M. Belger, A. Lenox-Smith and D. Price, Excess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease Among Patients with Vascular Dementia in a UK CPRD Population (1) 171–183
 Hascup, E.R., see Hascup, K.N. (1) 337–347
 Hascup, K.N. and E.R. Hascup, Soluble Amyloid- β_{42} Stimulates Glutamate Release through Activation of the $\alpha 7$ Nicotinic Acetylcholine Receptor (1) 337–347
- Hasegawa, Y., see Uekawa, K. (1) 127–133
 Hawkins, K.M. and L.E. Sergio, Adults at Increased Alzheimer's Disease Risk Display Cognitive-Motor Integration Impairment Associated with Changes in Resting-State Functional Connectivity: A Preliminary Study (3) 1161–1172
 He, R., see Zhou, X. (3) 843–855
 Hederstierna, C., see Idrizbegovic, E. (4) 1405–1410
 Heimbach, B., see Peter, J. (3) 991–1001
 Hendler, T., see Yogev-Seligmann, G. (2) 517–533
 Hensley, K. and P. Kursula, Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated
 Henstridge, C.M., see Pickett, E.K. (3) 787–800
 Herbst, V., see Vanderstichele, H.M.J. (3) 1121–1132
 Hernández-Guillamon, M., see Merino-Zamorano, C. (2) 677–691
 Herrmann, A.G., see Pickett, E.K. (3) 787–800
 Hersh, L.B., see Verma, N. (1) 259–272
 Himali, J.J., see Bangen, K.J. (4) 1553–1562
 Hird, M.A., P. Egeto, C.E. Fischer, G. Naglie and T.A. Schweizer, A Systematic Review and Meta-Analysis of On-Road Simulator and Cognitive Driving Assessment in Alzheimer's Disease and Mild Cognitive Impairment (2) 713–729
 Hishikawa, N., see Zhai, Y. (3) 893–905
 Hodges, J.R., see Dermody, N. (3) 801–816
 Hodges, J.R., see Langenhove, T.V. (3) 1033–1042
 Hofman, A., see Akoudad, S. (2) 497–503
 Hofman, A., see Araújo, L.F. (2) 451–461
 Hofman, A., see Chouraki, V. (3) 921–932
 Hofrichter, J., M. Krohn, T. Schumacher, C. Lange, B. Feistel, B. Walbroel and J. Pahnke, *Sideritis* spp. Extracts Enhance Memory and Learning in Alzheimer's β -Amyloidosis Mouse Models and Aged C57Bl/6 Mice (3) 967–980
 Höglund, K., see Tajeddinn, W. (1) 349–361
 Höglund, K., see Tajeddinn, W. (2) 621–630
 Holm, I.E., see Jakobsen, J.E. (4) 1617–1630
 Hong, C.H., see Roh, H.W. (2) 463–473
 Hong, H.S., see Kang, S. (4) 1563–1576
 Hong, J.W., see Suh, S.W. (2) 731–741
 Hooper, P.L., see Kasza, Á. (2) 557–571
 Horie, S., see Yamasaki, T. (2) 661–676
 Horváth, I., see Kasza, Á. (2) 557–571
 Hou, C., see Li, X. (4) 1577–1584
 Hsu, D.C., E.C. Mormino, A.P. Schultz, R.E. Amariglio, N.J. Donovan, D.M. Rentz, K.A.

- Johnson, R.A. Sperling and G.A. Marshall for the Harvard Aging Brain Study, Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly (3) 1097–1105
- Hu, C., see Russu, A. (2) 535–546
- Hu, Y., see Zhou, X. (3) 843–855
- Huang, E., see Li, W. (2) 393–402
- Huang, J., see Zhou, X. (3) 843–855
- Hugon, J., see Dumurgier, J. (4) 1411–1418
- Hüll, M., see Peter, J. (3) 991–1001
- Hunya, Á., see Kasza, Á. (2) 557–571
- Hwang, D., see Kang, S. (4) 1563–1576
- Hyman, B.T., see Pickett, E.K. (3) 787–800
- Ibáñez, A., see Pietto, M. (4) 1325–1340
- Ibrahimi, S., see Woody, S.K. (3) 1015–1031
- Ibrahim-Verbaas, C., see Chouraki, V. (3) 921–932
- Idrizbegovic, E., C. Hederstierna and U. Rosenhall, Mismatch Negativity and Ear Laterality in Alzheimer's Disease and in Mild Cognitive Impairment (4) 1405–1410
- Ii, Y., see Ueda, Y. (1) 315–325
- Ikram, M.A., see Akoudad, S. (2) 497–503
- Ikram, M.A., see Araújo, L.F. (2) 451–461
- Ikram, M.A., see Chouraki, V. (3) 921–932
- Inzitari, D., see Di Carlo, A. (2) 505–515
- Inzitari, M., see Di Carlo, A. (2) 505–515
- Irish, M., see Dermody, N. (3) 801–816
- Ito, J.-i., see Abdullah, M. (4) 1433–1441
- Ito, K., see Russu, A. (2) 535–546
- Ivachtchenko, A.V., Y. Lavrovsky and I. Okun, AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders (2) 583–620
- Ivanou, A., see Hanseeuw, B. (2) 651–660
- Izco, M., see Allué, J.A. (3) 773–785
- Jack Jr, C., see Wennberg, A.M.V. (2) 573–581
- Jack, C.R., see Krell-Roesch, J. (4) 1609–1616
- Jack, Jr., C.R., see Kantarci, K. (2) 547–556
- Jacobs, D., see De Vos, A. (4) 1523–1538
- Jakobsdottir, J., see Chouraki, V. (3) 921–932
- Jakobsen, J.E., M.G. Johansen, M. Schmidt, Y. Liu, R. Li, H. Callesen, M. Melnikova, M. Habekost, C. Matrone, Y. Bouter, T.A. Bayer, A.L. Nielsen, M. Duthie, P.E. Fraser, I.E. Holm and A.L. Jørgensen, Expression of the Alzheimer's Disease Mutations *AβPP695sw* and *PSEN1M146I* in Double-Transgenic Göttingen Minipigs (4) 1617–1630
- Janelidze, S., see Vanderstichele, H.M.J. (3) 1121–1132
- Janssens, J., see Vermeiren, Y. (3) 1079–1096
- Järemo, P., see Tajeddinn, W. (2) 621–630
- Jazin, E., see Farnsworth, B. (1) 209–219
- Jelic, V., see Tajeddinn, W. (2) 621–630
- Jentarra, G., see Perkins, M. (1) 95–106
- Jeong, H., see Kang, S. (4) 1563–1576
- Jeong, H., see Suh, S.W. (2) 731–741
- Jhoo, J.H., see Suh, S.W. (2) 731–741
- Ji, Z., see Zhou, X. (3) 843–855
- Jia, J., see Li, H. (2) 487–496
- Jia, S., see Li, X. (4) 1577–1584
- Jiang, Y., see Yu, J. (2) 693–704
- Jiao, J., see Li, X. (4) 1577–1584
- Jimenez, E., see Paholpak, P. (1) 327–335
- Jing, P., see El Gaamouch, F. (1) 15–29
- Johansen, M.G., see Jakobsen, J.E. (4) 1617–1630
- Johansson, B., see Lovas, J. (2) 631–638
- Johansson, K., see Lovas, J. (2) 631–638
- Johnson, K.A., see Hsu, D.C. (3) 1097–1105
- Jones, T.B., see Perkins, M. (1) 95–106
- Jørgensen, A.L., see Jakobsen, J.E. (4) 1617–1630
- Joshi, P., see Stravalaci, M. (4) 1485–1497
- Kaddoumi, A., see Qosa, H. (4) 1499–1516
- Kalaria, R., see Skrobot, O.A. (3) 981–989
- Kaller, C.P., see Peter, J. (3) 991–1001
- Kanba, S., see Yamasaki, T. (2) 661–676
- Kang, D.R., see Roh, H.W. (2) 463–473
- Kang, S., H. Jeong, J.-H. Baek, S.-J. Lee, S.-H. Han, H.J. Cho, H. Kim, H.S. Hong, Y.H. Kim, E.C. Yi, S.W. Seo, D.L. Na, D. Hwang and I. Mook-Jung, PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease (4) 1563–1576
- Kantarci, K., V.J. Lowe, T.G. Lesnick, N. Tosakulwong, K.R. Bailey, J.A. Fields, L.T. Shuster, S.M. Zuk, M.L. Senjem, M.M. Mielke, C. Gleason, C.R. Jack, Jr., W.A. Rocca and V.M. Miller, Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition (2) 547–556
- Karhunen, P., see Skrobot, O.A. (3) 981–989
- Kase, C., see Camargo, E.C. (4) 1597–1608
- Kasza, Á., Á. Hunya, Z. Frank, F. Fülöp, Z. Török, G. Balogh, M. Sántha, Á. Bálint, S. Bernáth, K.L.I.M. Blundell, C. Prodromou, I. Horváth, H.-J. Zeiler, P.L. Hooper, L. Vigh and B. Penke, Dihydropyridine Derivatives Modulate Heat Shock Responses and have a Neuroprotective Effect in a Transgenic Mouse Model of Alzheimer's Disease (2) 557–571
- Katz, M.J., see Mowrey, W.B. (4) 1585–1595

- Kay, K.R., see Pickett, E.K. (3) 787–800
 Kazokoglu, M.S., see Tajeddinn, W. (1) 349–361
 Kehoe, P.G., see Skrobot, O.A. (3) 981–989
 Kehr, J., see Tajeddinn, W. (1) 349–361
 Kehr, J., see Tajeddinn, W. (2) 621–630
 Kell, D.B., see Pretorius, E. (4) 1237–1256
 Keller, J.N., see Qosa, H. (4) 1499–1516
 Kelly-Hayes, M., see Camargo, E.C. (4) 1597–1608
 Kenny, R.A., see Feeney, J. (3) 1107–1114
 Kerssens, C.J., see Vijverberg, E.G.B. (4) 1287–1297
 Kettunen, P., see Andersson, C.-H. (4) 1353–1363
 Kettunen, P., see Farnsworth, B. (1) 209–219
 Kida, H., see Ueda, Y. (1) 315–325
 Kikuchi, M., see Oboshi, Y. (3) 817–830
 Kim, B.-J., see Suh, S.W. (2) 731–741
 Kim, D.K., see Roh, H.W. (2) 463–473
 Kim, H., see Kang, S. (4) 1563–1576
 Kim, J.L., see Suh, S.W. (2) 731–741
 Kim, K., see Suh, S.W. (2) 731–741
 Kim, K.W., see Suh, S.W. (2) 731–741
 Kim, S.-G., see Suh, S.W. (2) 731–741
 Kim, S.Y., see Roh, H.W. (2) 463–473
 Kim, T., see Suh, S.W. (2) 731–741
 Kim, T.H., see Suh, S.W. (2) 731–741
 Kim, Y.H., see Kang, S. (4) 1563–1576
 Kim-Mitsuyama, S., see Uekawa, K. (1) 127–133
 King, S., see Happich, M. (1) 171–183
 King-Kallimanis, B., see Feeney, J. (3) 1107–1114
 Kinsella, G.J., see Cavuoto, M.G. (3) 943–953
 Kira, J.-i., see Yamasaki, T. (2) 661–676
 Kirson, N.Y., see Happich, M. (1) 171–183
 Klewansky, T., see De Vos, A. (4) 1523–1538
 Klivényi, P., see Szalárdy, L. (2) 373–392
 Kloog, I., see Wilker, E.H. (4) 1315–1323
 Klöppel, S., see Peter, J. (3) 991–1001
 Knopman, D., see Wennberg, A.M.V. (2) 573–581
 Knopman, D.S., see Krell-Roesch, J. (4) 1609–1616
 Koek, H.L., see van de Vorst, I.E. (1) 117–125
 Koffie, R.M., see Pickett, E.K. (3) 787–800
 Koibuchi, N., see Uekawa, K. (1) 127–133
 König, A., see Ben-Sadoun, G. (4) 1299–1314
 Korojev, D., see Bobkova, N. (1) 289–301
 Köstering, L., see Peter, J. (3) 991–1001
 Koudstaal, P.J., see Akoudad, S. (2) 497–503
 Koutrakis, P., see Wilker, E.H. (4) 1315–1323
 Krell-Roesch, J., H. Ruider, V.J. Lowe, G.B. Stokin, A. Pink, R.O. Roberts, M.M. Mielke, D.S. Knopman, T.J. Christianson, M.M. Machulda, C.R. Jack, R.C. Petersen and Y.E. Geda, FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging (4) 1609–1616
 Krohn, M., see Hofrichter, J. (3) 967–980
 Krudop, W.A., see Vijverberg, E.G.B. (4) 1287–1297
 Kursula, P., see Hensley, K. (1) 1–14
 Kwak, K.P., see Suh, S.W. (2) 731–741
 Lahr, J., see Peter, J. (3) 991–1001
 Lamassa, M., see Di Carlo, A. (2) 505–515
 Lambert, J.-C., see Chouraki, V. (3) 921–932
 Landel, V., C. Annweiler, P. Millet, M. Morello and F. Féron, Vitamin D, Cognition and Alzheimer's Disease: The Therapeutic Benefit is in the D-Tails (2) 419–444
 Lange, C., see Hofrichter, J. (3) 967–980
 Langenhove, T.V., C.E. Leyton, O. Piguet and J.R. Hodges, Comparing Longitudinal Behavior Changes in the Primary Progressive Aphasias (3) 1033–1042
 Larson, E.B., see Chouraki, V. (3) 921–932
 Lauer, E., see Peter, J. (3) 991–1001
 Laukka, E.J., see Marseglia, A. (3) 1069–1078
 Launer, L.J., see Armstrong, J.J. (3) 1003–1013
 Launer, L.J., see Chouraki, V. (3) 921–932
 Lavrovsky, Y., see Ivachtchenko, A.V. (2) 583–620
 Le Ber, I., see Luis, E. (1) 303–313
 Lee, C., Best Linear Unbiased Prediction of Individual Polygenic Susceptibility to Sporadic Vascular Dementia (3) 1115–1119
 Lee, D.W., see Suh, S.W. (2) 731–741
 Lee, D.Y., see Suh, S.W. (2) 731–741
 Lee, J.-D., see Roh, H.W. (2) 463–473
 Lee, J.J., see Suh, S.W. (2) 731–741
 Lee, K.H., see Suh, S.W. (2) 731–741
 Lee, K.S., see Roh, H.W. (2) 463–473
 Lee, S.B., see Suh, S.W. (2) 731–741
 Lee, S.-J., see Kang, S. (4) 1563–1576
 Lee, Y., see Roh, H.W. (2) 463–473
 Legaz-García, A., see Marín-Muñoz, J. (1) 73–78
 Lemstra, A.W., see Staekenborg, S.S. (1) 135–142
 Lenox-Smith, A., see Happich, M. (1) 171–183
 Lerner, Y., see Yogev-Seligmann, G. (2) 517–533
 Lesnick, T.G., see Kantarci, K. (2) 547–556
 Leung, L., see Perkins, M. (1) 95–106
 Leyton, C.E., see Langenhove, T.V. (3) 1033–1042
 Lhommel, R., see Hanseeuw, B. (2) 651–660
 Li, C., see Gao, H.-l. (3) 1173–1192
 Li, H., J. Jia and Z. Yang, Mini-Mental State Examination in Elderly Chinese: A Population-Based Normative Study (2) 487–496
 Li, J., see Bamji-Mirza, M. (3) 875–892
 Li, J., see Yu, J. (2) 693–704
 Li, R., see Jakobsen, J.E. (4) 1617–1630
 Li, R., see Yu, J. (2) 693–704

- Li, W. and E. Huang, An Update on Type 2 Diabetes Mellitus as a Risk Factor for Dementia (2) 393–402
- Li, X., S. Jia, Z. Zhou, C. Hou, W. Zheng, P. Rong and J. Jiao, The Gesture Imitation in Alzheimer's Disease Dementia and Amnesic Mild Cognitive Impairment (4) 1577–1584
- Li, X., see Zhang, J. (1) 185–195
- Li, Y., see Bamji-Mirza, M. (3) 875–892
- Li, Z., see Zhang, J. (1) 185–195
- Liao, T.-Y., see Lin, C.-Y. (3) 1053–1067
- Libon, D.J., see Bangen, K.J. (4) 1553–1562
- Lichtenthaler, S.F., see Biella, G. (3) 1193–1207
- Liepert-Scarfone, I., see Glonnegger, H. (4) 1475–1484
- Li-Jung, L., see Paholpak, P. (1) 327–335
- Lim, K.Y., see Roh, H.W. (2) 463–473
- Limonta, E., see Venturelli, M. (4) 1631–1640
- Lin, C., see Lin, C.-Y. (3) 1053–1067
- Lin, C.-Y., Y.-S. Cheng, T.-Y. Liao, C. Lin, Z.-t. Chen, W.-I. Twu, C.-W. Chang, D. Tat-Wei Tan, R.-S. Liu, P.-h. Tu and R.P.-Y. Chen, Intranasal Administration of a Polyethylenimine-Conjugated Scavenger Peptide Reduces Amyloid- β Accumulation in a Mouse Model of Alzheimer's Disease (3) 1053–1067
- Lin, L., see Deng, Y. (4) 1419–1432
- Lipton, R.B., see Callisaya, M.L. (3) 1043–1052
- Lipton, R.B., see Mowrey, W.B. (4) 1585–1595
- Liraz, O., see Salomon-Zimri, S. (4) 1443–1458
- Liu, A., see Deng, Y. (4) 1419–1432
- Liu, E., see Russu, A. (2) 535–546
- Liu, F., see Wang, J. (3) 907–919
- Liu, G., see Wang, J. (3) 907–919
- Liu, M., see Verma, N. (1) 259–272
- Liu, Q.Y., see Bamji-Mirza, M. (3) 875–892
- Liu, R.-S., see Lin, C.-Y. (3) 1053–1067
- Liu, Y., see Jakobsen, J.E. (4) 1617–1630
- Liu, Z., see Zhang, J. (1) 185–195
- Lleo, A., see Pickett, E.K. (3) 787–800
- Loewenstein, D.A., see Mowrey, W.B. (4) 1585–1595
- Logroscino, G., see Sassi, C. (2) 475–485
- Lopera, F., see Pietto, M. (4) 1325–1340
- Lopez, O., see Chouraki, V. (3) 921–932
- López-Motos, D., see Marín-Muñoz, J. (1) 73–78
- López-Pousa, S., see Garre-Olmo, J. (4) 1341–1351
- Lovas, J., S.-M. Fereshtehnejad, P. Cermakova, C. Lundberg, B. Johansson, K. Johansson, B. Winblad, M. Eriksdotter and D. Religa, Assessment and Reporting of Driving Fitness in Patients with Dementia in Clinical Practice: Data from SveDem, the Swedish Dementia Registry (2) 631–638
- Love, S., see Skrobot, O.A. (3) 981–989
- Lovell, M.A., B.C. Lynn, S. Fister, M. Bradley-Whitman, M.P. Murphy, T.L. Beckett and C.M. Norris, A Novel Small Molecule Modulator of Amyloid Pathology (1) 273–287
- Lowe, V.J., see Kantarci, K. (2) 547–556
- Lowe, V.J., see Krell-Roesch, J. (4) 1609–1616
- Lu, M., see Russu, A. (2) 535–546
- Lue, L.-F., see Bamji-Mirza, M. (3) 875–892
- Luis, E., A. Ortiz, L. Eudave, S. Ortega-Cubero, B. Borroni, J. van der Zee, S. Gazzina, P. Caroppo, E. Rubino M.A., F. D'Agata, I. Le Ber, I. Santana, G. Cunha, M.R. Almeida, C. Boutoleau-Bretonnière, D. Hannequin, D. Wallon, I. Rainero, D. Galimberti, C.V. Broeckhoven, M.A. Pastor and P. Pastor, Neuroimaging Correlates of Frontotemporal Dementia Associated with SQSTM1 Mutations (1) 303–313
- Lundberg, C., see Lovas, J. (2) 631–638
- Lunet, N., see Moreira, A. (1) 85–93
- Luo, X., see Neugroschl, J. (1) 69–72
- Lutsey, P.L., see González, H.M. (3) 955–965
- Luz, I., see Salomon-Zimri, S. (4) 1443–1458
- Ly, H., see Verma, N. (1) 259–272
- Ly, S., see Perkins, M. (1) 95–106
- Lynn, B.C., see Lovell, M.A. (1) 273–287
- Ma, M., see Uekawa, K. (1) 127–133
- Machulda, M.M., see Krell-Roesch, J. (4) 1609–1616
- Maeda, M., see Ueda, Y. (1) 315–325
- Maioli, S., see Tajeddinn, W. (1) 349–361
- Malek-Ahmadi, M., S.E. Perez, K. Chen and E.J. Mufson, Neuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly (4) 1641–1652
- Maliszewska-Cyna, E., K. Xhima and I. Aubert, A Comparative Study Evaluating the Impact of Physical Exercise on Disease Progression in a Mouse Model of Alzheimer's Disease (1) 243–257
- Manera, V., see Ben-Sadoun, G. (4) 1299–1314
- Manera, V., see David, R. (4) 1365–1373
- Manes, F., see Pietto, M. (4) 1325–1340
- Manzanares, J., see Campanari, M.-L. (3) 831–841
- Manzanares-Sánchez, S., see Marín-Muñoz, J. (1) 73–78
- Marín-Muñoz, J., M.F. Noguera-Perea, E. Gómez-Tortosa, D. López-Motos, M. Antequera-Torres, B. Martínez-Herrada, S. Manzanares-Sánchez,

- L. Vivancos-Moreau, A. Legaz-García, A. Rábano-Gutiérrez del Arroyo and C. Antúnez-Almagro, Novel Mutation (Gly212Val) in the PS2 Gene Associated with Early-Onset Familial Alzheimer's Disease (1) 73–78
- Marino, S., see Naro, A. (4) 1375–1388
- Marra, A., see Naro, A. (4) 1375–1388
- Marseglia, A., L. Fratiglioni, E.J. Laukka, G. Santoni, N.L. Pedersen, L. Bäckman and W. Xu, Early Cognitive Deficits in Type 2 Diabetes: A Population-Based Study (3) 1069–1078
- Marshall, G.A., see Hsu, D.C. (3) 1097–1105
- Martin, J.-J., see Vermeiren, Y. (3) 1079–1096
- Martínez-Herrada, B., see Marín-Muñoz, J. (1) 73–78
- Martínez-Pinilla, E., see del Valle, E. (2) 639–650
- Martinez-Ramirez, S., see Wilker, E.H. (4) 1315–1323
- Martiskainen, M., see Skrobot, O.A. (3) 981–989
- Matrone, C., see Jakobsen, J.E. (4) 1617–1630
- Matsuda, S., see Gao, H.-I. (3) 1173–1192
- Matysiak, W., see Mohseni, H.K. (3) 933–942
- Mauroo, K., see Vanderstichele, H.M.J. (3) 1121–1132
- Mauray, F., see Chouraki, V. (3) 921–932
- Mayeux, R., see Chouraki, V. (3) 921–932
- Mazzanti, M., see Stravalaci, M. (4) 1485–1497
- McKee, A.C., see Bangen, K.J. (4) 1553–1562
- McKnight, A.J., see Skrobot, O.A. (3) 981–989
- Meckel, J.P., see Perkins, M. (1) 95–106
- Mecocci, P., see Skrobot, O.A. (3) 981–989
- Medvinskaya, N., see Bobkova, N. (1) 289–301
- Melnikova, M., see Jakobsen, J.E. (4) 1617–1630
- Mendez, M.F., see Paholpak, P. (1) 327–335
- Merino-Zamorano, C., S. Fernández-de Retana, A. Montañaola, A. Battle, J. Saint-Pol, C. Mysiorek, F. Gosselet, J. Montaner and M. Hernández-Guillamon, Modulation of Amyloid- β_{1-40} Transport by ApoA1 and ApoJ Across an *in vitro* Model of the Blood-Brain Barrier (2) 677–691
- Michaelson, D.M., see Salomon-Zimri, S. (4) 1443–1458
- Michikawa, M., see Abdullah, M. (4) 1433–1441
- Mielke, M.M., see Kantarci, K. (2) 547–556
- Mielke, M.M., see Krell-Roesch, J. (4) 1609–1616
- Mielke, M.M., see Wennberg, A.M.V. (2) 573–581
- Migliore, L., see Grossi, E. (4) 1517–1522
- Miklossy, J., Bacterial Amyloid and DNA are Important Constituents of Senile Plaques: Further Evidence of the Spirochetal and Biofilm Nature of Senile Plaques (4) 1459–1473
- Milić, A.P., see Mohseni, H.K. (3) 933–942
- Miller, V.M., see Kantarci, K. (2) 547–556
- Millet, P., see Landel, V. (2) 419–444
- Milovanovic, M., see Tajeddinn, W. (2) 621–630
- Minkova, L., see Peter, J. (3) 991–1001
- Minthon, L., see Andersson, C.-H. (4) 1353–1363
- Miraglia, F., see Rossini, P.M. (4) 1389–1393
- Mirza, S.S., see Araújo, L.F. (2) 451–461
- Mitnitski, A., see Armstrong, J.J. (3) 1003–1013
- Mittleman, M.A., see Wilker, E.H. (4) 1315–1323
- Mohamed, L.A., see Qosa, H. (4) 1499–1516
- Mohseni, H.K., D. Cowan, D.R. Chettle, A.P. Milić, N. Priest, W. Matysiak, J. Atanackovic, S.H. Byun and W.V. Prestwich, A Pilot Study Measuring Aluminum in Bone in Alzheimer's Disease and control Subjects Using *in vivo* Neutron Activation Analysis (3) 933–942
- Möller, C., see Vijverberg, E.G.B. (4) 1287–1297
- Montaner, J., see Merino-Zamorano, C. (2) 677–691
- Montañaola, A., see Merino-Zamorano, C. (2) 677–691
- Mook-Jung, I., see Kang, S. (4) 1563–1576
- Moon, S.W., see Suh, S.W. (2) 731–741
- Moreira, A., M.J. Diógenes, A. de Mendonça, N. Lunet and H. Barros, Chocolate Consumption is Associated with a Lower Risk of Cognitive Decline (1) 85–93
- Morello, M., see Landel, V. (2) 419–444
- Morihara, R., see Zhai, Y. (3) 893–905
- Mormino, E.C., see Hsu, D.C. (3) 1097–1105
- Mosley, T.H., see González, H.M. (3) 955–965
- Mostofsky, E., see Wilker, E.H. (4) 1315–1323
- Mowrey, W.B., R.B. Lipton, M.J. Katz, W.S. Ramratan, D.A. Loewenstein, M.E. Zimmerman and H. Buschke, Memory Binding Test Predicts Incident Amnesic Mild Cognitive Impairment (4) 1585–1595
- Mufson, E.J., see Malek-Ahmadi, M. (4) 1641–1652
- Mukherjee, S., see Chouraki, V. (3) 921–932
- Munafò, M., see Skrobot, O.A. (3) 981–989
- Murabito, J.M., see Camargo, E.C. (4) 1597–1608
- Murgas, P., see Eugenín, J. (3) 857–873
- Murphy, M.P., see Lovell, M.A. (1) 273–287
- Muscarà, N., see Naro, A. (4) 1375–1388
- Muti, E., see Venturelli, M. (4) 1631–1640
- Mysiorek, C., see Merino-Zamorano, C. (2) 677–691
- Na, D.L., see Kang, S. (4) 1563–1576
- Na, D.L., see Roh, H.W. (2) 463–473
- Nabeka, H., see Gao, H.-I. (3) 1173–1192
- Nagely, A.C., see Vidoni, E.D. (1) 161–170
- Naglie, G., see Hird, M.A. (2) 713–729

- Najem, D., see Bamji-Mirza, M. (3) 875–892
- Nakagata, N., see Uekawa, K. (1) 127–133
- Nakagawa, T., see Uekawa, K. (1) 127–133
- Nakamura, N., see Yamasaki, T. (2) 661–676
- Nakano, Y., see Zhai, Y. (3) 893–905
- Nardo, E., see Biella, G. (3) 1193–1207
- Naro, A., F. Corallo, S. De Salvo, A. Marra, G. Di Lorenzo, N. Muscarà, M. Russo, S. Marino, R. De Luca, P. Bramanti and R.S. Calabrò, Promising Role of Neuromodulation in Predicting the Progression of Mild Cognitive Impairment to Dementia (4) 1375–1388
- Nation, D.A., see Bangen, K.J. (4) 1553–1562
- Navarrete, F., see Campanari, M.-L. (3) 831–841
- Navarro, A., see del Valle, E. (2) 639–650
- Nekrasov, P., see Bobkova, N. (1) 289–301
- Nesterova, I., see Bobkova, N. (1) 289–301
- Neugroschl, J., M. Sewell, A. De La Fuente, M. Umpierre, X. Luo and M. Sano, Attitudes and Perceptions of Research in Aging and Dementia in an Urban Minority Population (1) 69–72
- Newberg, A., see Amen, D.G. (1) 237–241
- Ni, M., see Wang, J. (3) 907–919
- Nicholas, C.L., see Cavuoto, M.G. (3) 943–953
- Nielsen, A.L., see Jakobsen, J.E. (4) 1617–1630
- Niessen, W.J., see Araújo, L.F. (2) 451–461
- Nilsson, S., see Andersson, C.-H. (4) 1353–1363
- Nissen, C., see Peter, J. (3) 991–1001
- Noguera-Perea, M.F., see Marín-Muñoz, J. (1) 73–78
- Noh, J.S., see Roh, H.W. (2) 463–473
- Normann, C., see Peter, J. (3) 991–1001
- Norris, C.M., see Lovell, M.A. (1) 273–287
- Nunome, M., see Abdullah, M. (4) 1433–1441
- O'Regan, C., see Feeney, J. (3) 1107–1114
- Oboshi, Y., M. Kikuchi, T. Terada, E. Yoshikawa, T. Bunai and Y. Ouchi, Alterations in Phase-Related Prefrontal Activation During Cognitive Tasks and Nicotinic $\alpha 4\beta 2$ Receptor Availability in Alzheimer's Disease (3) 817–830
- Offen, D., see Salomon-Zimri, S. (4) 1443–1458
- Ogueta, S., see Allué, J.A. (3) 773–785
- Ohta, Y., see Zhai, Y. (3) 893–905
- Ohyagi, Y., see Yamasaki, T. (2) 661–676
- Okun, I., see Ivachtchenko, A.V. (2) 583–620
- Omalu, B., see Amen, D.G. (1) 237–241
- Ong, B., see Cavuoto, M.G. (3) 943–953
- Oren, N., see Yogev-Seligmann, G. (2) 517–533
- Ortega-Cubero, S., see Luis, E. (1) 303–313
- Ortiz, A., see Luis, E. (1) 303–313
- Otahal, P., see Callisaya, M.L. (3) 1043–1052
- Ouchi, Y., see Oboshi, Y. (3) 817–830
- Pahnke, J., see Hofrichter, J. (3) 967–980
- Paholpak, P., L. Li-Jung, D.R. Carr, E. Jimenez, R.J. Barrows, V. Sabodash and M.F. Mendez, Prolonged Visual Facial Grasp in Frontotemporal Dementia (1) 327–335
- Pai, M.-C., see Tsai, C.-L. (1) 143–159
- Pan, S., see Zhou, X. (3) 843–855
- Panza, F., see Di Carlo, A. (2) 505–515
- Panza, F., see Skrobot, O.A. (3) 981–989
- Paquet, C., see Dumurgier, J. (4) 1411–1418
- Park, J.H., see Suh, S.W. (2) 731–741
- Park, J.Y., see Suh, S.W. (2) 731–741
- Parra, M.A., see Pietto, M. (4) 1325–1340
- Parrado-Fernández, C., see Tajeddinn, W. (1) 349–361
- Pascual-Lucas, M., see Allué, J.A. (3) 773–785
- Passmore, P.A., see Skrobot, O.A. (3) 981–989
- Pastor, M.A., see Luis, E. (1) 303–313
- Pastor, P., see Luis, E. (1) 303–313
- Pedersen, N.L., see Marseglia, A. (3) 1069–1078
- Pemberton, H., see Brodtmann, A. (1) 79–83
- Penke, B., see Kasza, Á. (2) 557–571
- Penninkilampi, R., H.M. Brothers and G.D. Eslick, Pharmacological Agents Targeting γ -Secretase Increase Risk of Cancer and Cognitive Decline in Alzheimer's Disease Patients: A Systematic Review and Meta-Analysis (4) 1395–1404
- Peoples, R.W., see Peters, C. (1) 197–207
- Perales, J., O. Turró-Garriga, J. Gascón-Bayarri, R. Reñé-Ramírez and J.L. Conde-Sala, The Longitudinal Association Between a Discrepancy Measure of Anosognosia in Patients with Dementia, Caregiver Burden and Depression (3) 1133–1143
- Perez, S.E., see Malek-Ahmadi, M. (4) 1641–1652
- Pérez-Grijalba, V., see Allué, J.A. (3) 773–785
- Perkins, M., A.B. Wolf, B. Chavira, D. Shonebarger, J.P. Meckel, L. Leung, L. Ballina, S. Ly, A. Saini, T.B. Jones, J. Vallejo, G. Jentarra and J. Valla, Altered Energy Metabolism Pathways in the Posterior Cingulate in Young Adult Apolipoprotein E $\epsilon 4$ Carriers (1) 95–106
- Persson, T., see Tajeddinn, W. (1) 349–361
- Pesini, P., see Allué, J.A. (3) 773–785
- Pessi, T., see Skrobot, O.A. (3) 981–989
- Peter, J., J. Lahr, L. Minkova, E. Lauer, M.J. Grothe, S. Teipel, L. Köstering, C.P. Kaller, B. Heimbach, M. Hüll, C. Normann, C. Nissen, J. Reis and S. Klöppel, Contribution of the Cholinergic System to Verbal Memory Performance in Mild Cognitive Impairment (3) 991–1001
- Peters, A., see Vijverberg, E.G.B. (4) 1287–1297

- Peters, C., F.J. Sepúlveda, E.J. Fernández-Pérez, R.W. Peoples and L.G. Aguayo, The Level of NMDA Receptor in the Membrane Modulates Amyloid- β Association and Perforation (1) 197–207
- Petersen, R.C., see Krell-Roesch, J. (4) 1609–1616
- Petersen, R.C., see Wennberg, A.M.V. (2) 573–581
- Peuckert, C., see Farnsworth, B. (1) 209–219
- Pickett, E.K., R.M. Koffie, S. Wegmann, C.M. Henstridge, A.G. Herrmann, M. Colom-Cadena, A. Lleo, K.R. Kay, M. Vaught, R. Soberman, D.M. Walsh, B.T. Hyman and T.L. Spire-Jones, Non-Fibrillar Oligomeric Amyloid- β within Synapses (3) 787–800
- Pietto, M., M.A. Parra, N. Trujillo, F. Flores, A.M. García, J. Bustin, P. Richly, F. Manes, F. Lopera, A. Ibáñez and S. Baez, Behavioral and Electrophysiological Correlates of Memory Binding Deficits in Patients at Different Risk Levels for Alzheimer's Disease (4) 1325–1340
- Piguet, O., see Dermody, N. (3) 801–816
- Piguet, O., see Langenhove, T.V. (3) 1033–1042
- Pijnenburg, Y.A.L., see Staekenborg, S.S. (1) 135–142
- Pijnenburg, Y.A.L., see Vijverberg, E.G.B. (4) 1287–1297
- Pijnenburg, Y.A.L., see Willemse, E.A.J. (1) 107–116
- Pike, K.E., see Cavuoto, M.G. (3) 943–953
- Pink, A., see Krell-Roesch, J. (4) 1609–1616
- Pires, M.M., see Taipa, R. (2) 403–417
- Pirzada, A., see González, H.M. (3) 955–965
- Pizzi, E., see Stravalaci, M. (4) 1485–1497
- Pradier, C., see David, R. (4) 1365–1373
- Praticò, D., see Di Meco, A. (2) 367–372
- Prestwich, W.V., see Mohseni, H.K. (3) 933–942
- Pretorius, E., J. Bester and D.B. Kell, A Bacterial Component to Alzheimer's-Type Dementia Seen via a Systems Biology Approach that Links Iron Dysregulation and Inflammagen Shedding to Disease (4) 1237–1256
- Prevot, M., see Dumurgier, J. (4) 1411–1418
- Price, D., see Happich, M. (1) 171–183
- Priest, N., see Mohseni, H.K. (3) 933–942
- Prins, N.D., see Vijverberg, E.G.B. (4) 1287–1297
- Prodromou, C., see Kasza, Á. (2) 557–571
- Protein Tau (1) 1–14
- Qiao, S., see Wang, J. (3) 907–919
- Qosa, H., L.A. Mohamed, S.B. Al Rihani, Y.S. Batarseh, Q.-V. Duong, J.N. Keller and A. Kaddoumi, High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity (4) 1499–1516
- Quenon, L., see Hanseeuw, B. (2) 651–660
- Rábano-Gutiérrez del Arroyo, A., see Marín-Muñoz, J. (1) 73–78
- Raghavendra, C., see Amen, D.G. (1) 237–241
- Rainero, I., see Luis, E. (1) 303–313
- Raje, S., see Russu, A. (2) 535–546
- Raji, C.A., see Amen, D.G. (1) 237–241
- Ramratan, W.S., see Mowrey, W.B. (4) 1585–1595
- Reed, C., see Happich, M. (1) 171–183
- Reis, J., see Peter, J. (3) 991–1001
- Reitz, C., see Chouraki, V. (3) 921–932
- Religa, D., see Lovas, J. (2) 631–638
- Reñé-Ramírez, R., see Perales, J. (3) 1133–1143
- Rentz, D.M., see Hsu, D.C. (3) 1097–1105
- Richly, P., see Pietto, M. (4) 1325–1340
- Robberecht, C., see De Vos, A. (4) 1523–1538
- Robert, P., see Ben-Sadoun, G. (4) 1299–1314
- Robert, P., see David, R. (4) 1365–1373
- Roberts, R.O., see Krell-Roesch, J. (4) 1609–1616
- Roberts, R.O., see Wennberg, A.M.V. (2) 573–581
- Rocca, W.A., see Kantarci, K. (2) 547–556
- Rocha, N.P., see Salem, H. (3) 1209–1230
- Rockwood, K., see Armstrong, J.J. (3) 1003–1013
- Rodríguez, C.J., see González, H.M. (3) 955–965
- Rogaeva, E., see Bamji-Mirza, M. (3) 875–892
- Roh, H.W., C.H. Hong, Y. Lee, K.S. Lee, K.J. Chang, D.R. Kang, J.-D. Lee, S.H. Choi, S.Y. Kim, D.L. Na, S.W. Seo, D.K. Kim, J.H. Back, Y.K. Chung, K.Y. Lim, J.S. Noh and S.J. Son, Clinical Conversion or Reversion of Mild Cognitive Impairment in Community versus Hospital Based Studies: GDEMCIS (Gwangju Dementia and Mild Cognitive Impairment Study) and CREDOS (Clinical Research Center for Dementia of South Korea) (2) 463–473
- Rong, P., see Li, X. (4) 1577–1584
- Rongve, A., see Brønneck, K. (4) 1277–1285
- Rosenhall, U., see Idrizbegovic, E. (4) 1405–1410
- Rossi, A., see Stravalaci, M. (4) 1485–1497
- Rossini, P.M., R. Di Iorio, G. Granata, F. Miraglia and F. Vecchio, From Mild Cognitive Impairment to Alzheimer's Disease: A New Perspective in the "Land" of Human Brain Reactivity and Connectivity (4) 1389–1393
- Rubino M.A, E., see Luis, E. (1) 303–313
- Ruider, H., see Krell-Roesch, J. (4) 1609–1616
- Rundek, T., see González, H.M. (3) 955–965
- Russo, M., see Naro, A. (4) 1375–1388

- Russu, A., M.N. Samtani, S. Xu, O.J. Adedokun, M. Lu, K. Ito, B. Corrigan, S. Raje, E. Liu, H.R. Brashear, S. Styren and C. Hu, Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab (2) 535–546
- Ryu, S.-H., see Suh, S.W. (2) 731–741
- Sabodash, V., see Paholpak, P. (1) 327–335
- Sacco, G., see Ben-Sadoun, G. (4) 1299–1314
- Sáez-Valero, J., see Campanari, M.-L. (3) 831–841
- Saini, A., see Perkins, M. (1) 95–106
- Saint-Pol, J., see Merino-Zamorano, C. (2) 677–691
- Sakuma, H., see Ueda, Y. (1) 315–325
- Saladie, D.G., see Bolívar, J.C.C. (2) 705–712
- Salem, H., N.P. Rocha, G.D. Colpo and A.L. Teixeira, Moving from the Dish to the Clinical Practice: A Decade of Lessons and Perspectives from the Pre-Clinical and Clinical Stem Cell Studies for Alzheimer's Disease (3) 1209–1230
- Salmona, M., see Stravalaci, M. (4) 1485–1497
- Salomon-Zimri, S., M.J. Glat, Y. Barhum, I. Luz, A. Boehm-Cagan, O. Liraz, T. Ben-Zur, D. Offen and D.M. Michaelson, Reversal of ApoE4-Driven Brain Pathology by Vascular Endothelial Growth Factor Treatment (4) 1443–1458
- Samokhin, A., see Bobkova, N. (1) 289–301
- Samtani, M.N., see Russu, A. (2) 535–546
- Sano, M., see Neugroschl, J. (1) 69–72
- Santana, I., see Luis, E. (1) 303–313
- Sántha, M., see Kasza, Á. (2) 557–571
- Santoni, G., see Marseglia, A. (3) 1069–1078
- Sarasa, L., see Allué, J.A. (3) 773–785
- Sarasa, M., see Allué, J.A. (3) 773–785
- Sassi, C., R. Capozzo, R. Gibbs, C. Crews, C. Zecca, S. Arcuti, M. Copetti, M.R. Barulli, V. Brescia, A.B. Singleton and G. Logroschino, A Novel Splice-Acceptor Site Mutation in GRN (c.709-2 A>T) Causes Frontotemporal Dementia Spectrum in a Large Family from Southern Italy (2) 475–485
- Satoh, M., see Ueda, Y. (1) 315–325
- Savva, G.M., see Feeney, J. (3) 1107–1114
- Scafato, E., see Di Carlo, A. (2) 505–515
- Scarpini, E., see Galimberti, D. (2) 445–449
- Scheltens, P., see Staekenborg, S.S. (1) 135–142
- Scheltens, P., see Vijverberg, E.G.B. (4) 1287–1297
- Schmidt, M., see Jakobsen, J.E. (4) 1617–1630
- Schultz, A.P., see Hsu, D.C. (3) 1097–1105
- Schumacher, T., see Hofrichter, J. (3) 967–980
- Schuster, J. and S.A. Funke, Methods for the Specific Detection and Quantitation of Amyloid- β Oligomers in Cerebrospinal Fluid (1) 53–67
- Schwartz, J., see Wilker, E.H. (4) 1315–1323
- Schweizer, T.A., see Hird, M.A. (2) 713–729
- Sciver, A.V., see Vidoni, E.D. (1) 161–170
- Sengpiel, F., see Bobkova, N. (1) 289–301
- Senjem, M.L., see Kantarci, K. (2) 547–556
- Senju, S., see Uekawa, K. (1) 127–133
- Seo, J., see Suh, S.W. (2) 731–741
- Seo, S.W., see Kang, S. (4) 1563–1576
- Seo, S.W., see Roh, H.W. (2) 463–473
- Sepúlveda, F.J., see Peters, C. (1) 197–207
- Sergio, L.E., see Hawkins, K.M. (3) 1161–1172
- Seripa, D., see Skrobot, O.A. (3) 981–989
- Seshadri, S., see Bangen, K.J. (4) 1553–1562
- Seshadri, S., see Camargo, E.C. (4) 1597–1608
- Seshadri, S., see Chouraki, V. (3) 921–932
- Sewell, M., see Neugroschl, J. (1) 69–72
- Shahnaz, T., see Tajeddinn, W. (2) 621–630
- Shang, J., see Zhai, Y. (3) 893–905
- Shen, L., see Han, B. (4) 1539–1552
- Shimokawa, T., see Gao, H.-I. (3) 1173–1192
- Shonebarger, D., see Perkins, M. (1) 95–106
- Shu, N., see Zhang, J. (1) 185–195
- Shuster, L.T., see Kantarci, K. (2) 547–556
- Sieben, A., see Vermeiren, Y. (3) 1079–1096
- Singleton, A.B., see Sassi, C. (2) 475–485
- Skoog, I., see Andersson, C.-H. (4) 1353–1363
- Skrobot, O.A., A.J. McKnight, P.A. Passmore, D. Seripa, P. Mecocci, F. Panza, R. Kalaria, G. Wilcock, M. Munafò, T. Erkinjuntti, P. Karhunen, T. Pessi, M. Martiskainen, S. Love, the Genetic and Environmental Risk for Alzheimer's disease Consortium (GERAD1) and P.G. Kehoe, A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative Cohort (3) 981–989
- Soberman, R., see Pickett, E.K. (3) 787–800
- Solfrizzi, V., see Di Carlo, A. (2) 505–515
- Sollima, A., see Venturelli, M. (4) 1631–1640
- Son, S.J., see Roh, H.W. (2) 463–473
- Sousa, A.L., see Taipa, R. (2) 403–417
- Sousa, N., see Taipa, R. (2) 403–417
- Sperling, R.A., see Hsu, D.C. (3) 1097–1105
- Spire-Jones, T.L., see Pickett, E.K. (3) 787–800
- Srikanth, V.K., see Callisaya, M.L. (3) 1043–1052
- Staekenborg, S.S., Y.A.L. Pijnenburg, A.W. Lemstra, P. Scheltens and W.M. vd Flier, Dementia and Rapid Mortality: Who is at Risk? (1) 135–142
- Stek, M.L., see Vijverberg, E.G.B. (4) 1287–1297
- Stocco, A., see Grossi, E. (4) 1517–1522

- Stokin, G.B., see Krell-Roesch, J. (4) 1609–1616
- Stoops, E., see Vanderstichele, H.M.J. (3) 1121–1132
- Stravalaci, M., L. Tapella, M. Beeg, A. Rossi, P. Joshi, E. Pizzi, M. Mazzanti, C. Balducci, G. Forloni, E. Biasini, M. Salmona, L. Diomedea, R. Chiesa and M. Gobbi, The Anti-Prion Antibody 15B3 Detects Toxic Amyloid- β Oligomers (4) 1485–1497
- Struyfs, H., see De Vos, A. (4) 1523–1538
- Stupak, J., see Bamji-Mirza, M. (3) 875–892
- Styren, S., see Russu, A. (2) 535–546
- Suh, S.W., J.W. Han, J.Y. Park, J.W. Hong, K. Kim, T. Kim, K.H. Lee, G. Han, H. Jeong, J. Seo, T.H. Kim, D.Y. Lee, D.W. Lee, S.-H. Ryu, S.-G. Kim, J.C. Youn, J.H. Jhoo, J.L. Kim, S.B. Lee, J.J. Lee, K.P. Kwak, B.-J. Kim, S.W. Moon, J.H. Park and K.W. Kim, Impacts of Illiteracy on the Risk of Dementia: A Global Health Perspective (2) 731–741
- Sun, Z., see Zhai, Y. (3) 893–905
- Szalárdy, L., D. Zádori, P. Klivényi and L. Vécsei, The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis (2) 373–392
- Tabei, K.-i., see Ueda, Y. (1) 315–325
- Taipa, R., A.L. Sousa, M.M. Pires and N. Sousa, Does the Interplay Between Aging and Neuroinflammation Modulate Alzheimer's Disease Clinical Phenotypes? A Clinico-Pathological Perspective (2) 403–417
- Tajeddinn, W., S.-M. Fereshtehnejad, M.S. Ahmed, T. Yoshitake, J. Kehr, T. Shahnaz, M. Milovanovic, H. Behbahani, K. Höglund, B. Winblad, A. Cedazo-Minguez, V. Jelic, P. Järemo and D. Aarsland, Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers (2) 621–630
- Tajeddinn, W., T. Persson, J. Calvo-Garrido, M.S. Ahmed, S. Maioli, S. Vijayaraghavan, M.S. Kazokoglu, C. Parrado-Fernández, T. Yoshitake, J. Kehr, P. Francis, B. Winblad, K. Höglund, A. Cedazo-Minguez and D. Aarsland, Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease (1) 349–361
- Takase, H., see Abdullah, M. (4) 1433–1441
- Tan, Z.S., see Camargo, E.C. (4) 1597–1608
- Tanaka, E., see Yamasaki, T. (2) 661–676
- Tang, W., J. Cheng, Z.-Y. Wang, K.-Y. Chen, Z.-M. Han, Q.-H. Wang and Y.-Y. Yao, The Synergistic Roles of the Chronic Prenatal and Offspring Stress Exposures in Impairing Offspring Learning and Memory (1) 221–236
- Tannorella, P., see Grossi, E. (4) 1517–1522
- Tapella, L., see Stravalaci, M. (4) 1485–1497
- Tarraf, W., see González, H.M. (3) 955–965
- Tatarnikova, O., see Bobkova, N. (1) 289–301
- Tat-Wei Tan, D., see Lin, C.-Y. (3) 1053–1067
- Teipel, S., see Peter, J. (3) 991–1001
- Teixeira, A.L., see Salem, H. (3) 1209–1230
- Terada, T., see Oboshi, Y. (3) 817–830
- Teunissen, C.E., see Willemse, E.A.J. (1) 107–116
- Tiemeier, H., see Araújo, L.F. (2) 451–461
- Tifratene, K., see David, R. (4) 1365–1373
- Tobimatsu, S., see Yamasaki, T. (2) 661–676
- Tolivia, J., see del Valle, E. (2) 639–650
- Tomimoto, H., see Ueda, Y. (1) 315–325
- Torices, S., see del Valle, E. (2) 639–650
- Török, Z., see Kasza, Á. (2) 557–571
- Tosakulwong, N., see Kantarci, K. (2) 547–556
- Trojano, L. and G. Gainotti, Drawing Disorders in Alzheimer's Disease and Other Forms of Dementia (1) 31–52
- Trujillo, N., see Pietto, M. (4) 1325–1340
- Tsai, C.-L., M.-C. Pai, J. Ukropec and B. Ukropcová, The Role of Physical Fitness in the Neurocognitive Performance of Task Switching in Older Persons with Mild Cognitive Impairment (1) 143–159
- Tu, P.-h., see Lin, C.-Y. (3) 1053–1067
- Turró-Garriga, O., see Garre-Olmo, J. (4) 1341–1351
- Turró-Garriga, O., see Perales, J. (3) 1133–1143
- Twu, W.-I., see Lin, C.-Y. (3) 1053–1067
- Tzourio, C., see Dumurgier, J. (4) 1411–1418
- Ueda, Y., M. Satoh, K.-i. Tabei, H. Kida, Y. Ii, M. Asahi, M. Maeda, H. Sakuma and H. Tomimoto, Neuropsychological Features of Microbleeds and Cortical Microinfarct Detected by High Resolution Magnetic Resonance Imaging (1) 315–325
- Uekawa, K., Y. Hasegawa, S. Senju, N. Nakagata, M. Ma, T. Nakagawa, N. Koibuchi and S. Kim-Mitsuyama, Intracerebroventricular Infusion of Angiotensin-(1–7) Ameliorates Cognitive Impairment and Memory Dysfunction in a Mouse Model of Alzheimer's Disease (1) 127–133

- Uitterlinden, A.G., see Chouraki, V. (3) 921–932
 Ukropcová, B., see Tsai, C.-L. (1) 143–159
 Ukropec, J., see Tsai, C.-L. (1) 143–159
 Umpierre, M., see Neugroschl, J. (1) 69–72
 Uphoff, E., see Vidoni, E.D. (1) 161–170
- Vaartjes, I., see van de Vorst, I.E. (1) 117–125
 Valla, J., see Perkins, M. (1) 95–106
 Vallejo, J., see Perkins, M. (1) 95–106
 van Berckel, B.N.M., see Vijverberg, E.G.B. (4) 1287–1297
 Van Broeckhoven, C., see De Vos, A. (4) 1523–1538
 Van Dam, D., see Vermeiren, Y. (3) 1079–1096
 van de Vorst, I.E., H.L. Koek, M.L. Bots and I. Vaartjes, Evaluation of Underlying Causes of Death in Patients with Dementia to Support Targeted Advance Care Planning (1) 117–125
 van der Flier, W.M., see Willemse, E.A.J. (1) 107–116
 van der Lee, S.J., see Chouraki, V. (3) 921–932
 van der Lugt, A., see Araújo, L.F. (2) 451–461
 van der Zee, J., see Luis, E. (1) 303–313
 van Duijn, C., see Chouraki, V. (3) 921–932
 Vanderstichele, H.M.J., S. Janelidze, L. Demeyer, E. Coart, E. Stoops, V. Herbst, K. Mauroo, B. Brix and O. Hansson, Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid A β ₄₂ and the Ratios of A β Isoforms Using Low Protein Binding Tubes (3) 1121–1132
 Vanmechelen, E., see De Vos, A. (4) 1523–1538
 Vardarajan, B., see Chouraki, V. (3) 921–932
 Varley, R.A., see Zimmerer, V.C. (3) 1145–1160
 Vaught, M., see Pickett, E.K. (3) 787–800
 vd Flier, W.M., see Staekenborg, S.S. (1) 135–142
 Vecchio, F., see Rossini, P.M. (4) 1389–1393
 Vecchiola, A., see Eugenín, J. (3) 857–873
 Vécsei, L., see Szalárdy, L. (2) 373–392
 Venturelli, M., A. Sollima, E. Cè, E. Limonta, A.V. Bisconti, A. Brasioli, E. Muti and F. Esposito, Effectiveness of Exercise- and Cognitive-Based Treatments on Salivary Cortisol Levels and Sundowning Syndrome Symptoms in Patients with Alzheimer's Disease (4) 1631–1640
 Verghese, J., see Callisaya, M.L. (3) 1043–1052
 Verma, N., H. Ly, M. Liu, J. Chen, H. Zhu, M. Chow, L.B. Hersh and F. Despa, Intraneuronal Amylin Deposition, Peroxidative Membrane Injury and Increased IL-1 β Synthesis in Brains of Alzheimer's Disease Patients with Type-2 Diabetes and in Diabetic HIP Rats (1) 259–272
 Vermeiren, Y., J. Janssens, T. Aerts, J.-J. Martin, A. Sieben, D. Van Dam and P.P. De Deyn, Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease (3) 1079–1096
 Vernooij, M.W., see Akoudad, S. (2) 497–503
 Vernooij, M.W., see Araújo, L.F. (2) 451–461
 Vidoni, E.D., A.S. Watts, J.M. Burns, C.S. Greer, R.S. Graves, A.V. Sciver, J.R. Black, S.K. Cooper, A.C. Nagely, E. Uphoff, J.M. Volmer and N.A. Bieberle, Feasibility of a Memory Clinic-Based Physical Activity Prescription Program (1) 161–170
 Vigh, L., see Kasza, Á. (2) 557–571
 Vijayaraghavan, S., see Tajeddinn, W. (1) 349–361
 Vijverberg, E.G.B., M.P. Wattjes, A. Dols, W.A. Krudop, C. Möller, A. Peters, C.J. Kerssens, F. Gossink, N.D. Prins, M.L. Stek, P. Scheltens, B.N.M. van Berckel, F. Barkhof and Y.A.L. Pijnenburg, Diagnostic Accuracy of MRI and Additional [¹⁸F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes (4) 1287–1297
 Viswanathan, A., see Wilker, E.H. (4) 1315–1323
 Vivancos-Moreau, L., see Marín-Muñoz, J. (1) 73–78
 Vogel, A.P., see Brodtmann, A. (1) 79–83
 Volmer, J.M., see Vidoni, E.D. (1) 161–170
 Volpina, O., see Bobkova, N. (1) 289–301
 von Bernhardi, R., see Eugenín, J. (3) 857–873
 Vorobyov, V., see Bobkova, N. (1) 289–301
- Walbroel, B., see Hofrichter, J. (3) 967–980
 Walker, D., see Bamji-Mirza, M. (3) 875–892
 Wallin, A., see Andersson, C.-H. (4) 1353–1363
 Wallon, D., see Luis, E. (1) 303–313
 Walsh, D.M., see Pickett, E.K. (3) 787–800
 Wang, H., see Han, B. (4) 1539–1552
 Wang, J., F. Ye, X. Cheng, X. Zhang, F. Liu, G. Liu, M. Ni, S. Qiao, W. Zhou and Y. Zhang, The Effects of LW-AFC on Intestinal Microbiome in Senescence-Accelerated Mouse Prone 8 Strain, a Mouse Model of Alzheimer's Disease (3) 907–919
 Wang, J., see Han, B. (4) 1539–1552
 Wang, M., see Han, B. (4) 1539–1552
 Wang, Q.-H., see Tang, W. (1) 221–236
 Wang, Y., see Han, B. (4) 1539–1552
 Wang, Y., see Zhang, J. (1) 185–195

- Wang, Z.-Y., see Gao, H.-I. (3) 1173–1192
Wang, Z.-Y., see Tang, W. (1) 221–236
Wattjes, M.P., see Vijverberg, E.G.B. (4) 1287–1297
Watts, A.S., see Vidoni, E.D. (1) 161–170
Wegmann, S., see Pickett, E.K. (3) 787–800
Wei, J., see Deng, Y. (4) 1419–1432
Weinstein, G., see Camargo, E.C. (4) 1597–1608
Wennberg, A.M.V., D. Gustafson, C.E. Hagen, R.O. Roberts, D. Knopman, C. Jack Jr, R.C. Petersen and M.M. Mielke, Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging (2) 573–581
White, L.R., see Armstrong, J.J. (3) 1003–1013
Wibrow, M., see Zimmerer, V.C. (3) 1145–1160
Wilcock, G., see Skrobot, O.A. (3) 981–989
Wilker, E.H., S. Martinez-Ramirez, I. Kloog, J. Schwartz, E. Mostofsky, P. Koutrakis, M.A. Mittleman and A. Viswanathan, Fine Particulate Matter, Residential Proximity to Major Roads, and Markers of Small Vessel Disease in a Memory Study Population (4) 1315–1323
Willemse, E.A.J., S. Durieux-Lu, W.M. van der Flier, Y.A.L. Pijnenburg, R. de Jonge and C.E. Teunissen, Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid (1) 107–116
Willeumier, K., see Amen, D.G. (1) 237–241
Winblad, B., see Lovas, J. (2) 631–638
Winblad, B., see Tajeddinn, W. (1) 349–361
Winblad, B., see Tajeddinn, W. (2) 621–630
Wolf, A.B., see Perkins, M. (1) 95–106
Wolf, P.A., see Bangen, K.J. (4) 1553–1562
Wong, S., see Dermody, N. (3) 801–816
Woody, S.K., H. Zhou, S. Ibrahimi, Y. Dong and L. Zhao, Human ApoE ϵ 2 Promotes Regulatory Mechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-type H⁺-ATPase (3) 1015–1031
Wright, C., see González, H.M. (3) 955–965

Xhima, K., see Maliszewska-Cyna, E. (1) 243–257
Xia, J., see El Gaamouch, F. (1) 15–29
Xiong, Z., see Deng, Y. (4) 1419–1432
Xu, M., see Zhou, X. (3) 843–855
Xu, S., see Russu, A. (2) 535–546
Xu, W., see Marseglia, A. (3) 1069–1078

Yamasaki, T., S. Horie, Y. Ohyagi, E. Tanaka, N. Nakamura, Y. Goto, S. Kanba, J.-i. Kira and S. Tobimatsu, A Potential VEP Biomarker for Mild Cognitive Impairment: Evidence from Selective Visual Deficit of Higher-Level Dorsal Pathway (2) 661–676
Yamashita, T., see Zhai, Y. (3) 893–905
Yan, Z., see Deng, Y. (4) 1419–1432
Yang, Z., see Bamji-Mirza, M. (3) 875–892
Yang, Z., see Li, H. (2) 487–496
Yao, Y.-Y., see Tang, W. (1) 221–236
Ye, F., see Wang, J. (3) 907–919
Yi, E.C., see Kang, S. (4) 1563–1576
Yogev-Seligmann, G., N. Oren, E.L. Ash, T. Hendler, N. Giladi and Y. Lerner, Altered Topology in Information Processing of a Narrated Story in Older Adults with Mild Cognitive Impairment (2) 517–533
Yoshikawa, E., see Oboshi, Y. (3) 817–830
Yoshitake, T., see Tajeddinn, W. (1) 349–361
Yoshitake, T., see Tajeddinn, W. (2) 621–630
Youn, J.C., see Suh, S.W. (2) 731–741
Yu, J., R. Li, Y. Jiang, L.S. Broster and J. Li, Altered Brain Activities Associated with Neural Repetition Effects in Mild Cognitive Impairment Patients (2) 693–704
Yu, L., see Chouraki, V. (3) 921–932
Yu, L., see Han, B. (4) 1539–1552

Zádori, D., see Szalárdy, L. (2) 373–392
Zecca, C., see Sassi, C. (2) 475–485
Zeiler, H.-J., see Kasza, Á. (2) 557–571
Zetterberg, H., see Andersson, C.-H. (4) 1353–1363
Zhai, Y., T. Yamashita, Y. Nakano, Z. Sun, J. Shang, T. Feng, R. Morihara, Y. Fukui, Y. Ohta, N. Hishikawa and K. Abe, Chronic Cerebral Hypoperfusion Accelerates Alzheimer's Disease Pathology with Cerebrovascular Remodeling in a Novel Mouse Model (3) 893–905
Zhang, J., Z. Liu, Z. Li, Y. Wang, Y. Chen, X. Li, K. Chen, N. Shu and Z. Zhang, Disrupted White Matter Network and Cognitive Decline in Type 2 Diabetes Patients (1) 185–195
Zhang, W., see Bamji-Mirza, M. (3) 875–892
Zhang, X., see Wang, J. (3) 907–919
Zhang, Y., see Wang, J. (3) 907–919
Zhang, Z., see Zhang, J. (1) 185–195
Zhao, L., see Woody, S.K. (3) 1015–1031
Zheng, W., see Li, X. (4) 1577–1584
Zhong, P., see Deng, Y. (4) 1419–1432
Zhou, H., see Woody, S.K. (3) 1015–1031
Zhou, W., see Wang, J. (3) 907–919
Zhou, X., J. Huang, S. Pan, M. Xu, R. He, Z. Ji and Y. Hu, Neurodegeneration-Like Pathological and Behavioral Changes in an AAV9-Mediated

- p25 Overexpression Mouse Model (3) 843–855
- Zhou, Z., see Li, X. (4) 1577–1584
- Zhu, H., see Verma, N. (1) 259–272
- Zimmerer, V.C., M. Wibrow and R.A. Varley, Formulaic Language in People with Probable Alzheimer’s Disease: A Frequency-Based Approach (3) 1145–1160
- Zimmerman, M.E., see Mowrey, W.B. (4) 1585–1595
- Zimmermann, B., see Farnsworth, B. (1) 209–219
- Zuk, S.M., see Kantarci, K. (2) 547–556